Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons

Rugi Bah; Yumi Sheehan; Xiaoying Li; Nicola Price; Tony Butler; Gregory J Dore; Jason Grebely; Andrew R Lloyd; Behzad Hajarizadeh; AusHep study group

doi:10.1016/j.drugpo.2024.104401

Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons

Int J Drug Policy. 2024 Apr 25:104401. doi: 10.1016/j.drugpo.2024.104401. Online ahead of print.

Authors

Rugi Bah¹, Yumi Sheehan², Xiaoying Li², Nicola Price², Tony Butler³, Gregory J Dore², Jason Grebely², Andrew R Lloyd², Behzad Hajarizadeh²; AusHep study group

Affiliations

¹ The Kirby Institute, UNSW, Sydney, New South Wales, Australia. Electronic address: rbah@kirby.unsw.edu.au.
² The Kirby Institute, UNSW, Sydney, New South Wales, Australia.
³ School of Population Health, UNSW, Sydney, New South Wales, Australia.

PMID: 38670855
DOI: 10.1016/j.drugpo.2024.104401

Abstract

Background: Prison-based blood-borne virus (BBV) surveillance is essential for evaluation of prevention and treatment programs for high-risk populations, such as people who inject drugs who are over-represented amongst those incarcerated. Regular triennial surveillance has been in place in Australian prisons for almost two decades, but has been focused to date only on new prison entrants. Recently, the Australian Hepatitis and risk survey in prisons (AusHep study) was established to provide improved surveillance via an expanded bio-behavioural survey representative of all people in prison, including those sentenced and those on remand. This paper aims to identify the challenges and facilitators in conducting bio-behavioural surveys for BBV infections in prison settings.

Methods: Randomly selected individuals in 23 prisons, representative of prisons and people in prison (male/female, security classification, rural location, Aboriginal or Torres Strait Islander), were offered point-of-care testing for HIV and hepatitis C (HCV) antibodies, hepatitis B virus surface (HBs) antigen, and HCV RNA (if HCV antibody positive). Data regarding risk behaviours, harm reduction measures, and prior BBV testing and treatment were collected by interview. Data was also collected on the challenges and facilitators encountered during planning and implementation at each participating prison.

Results: In the first round, AusHep recruited 1599 participants (98 % participation, 89 % male, median age 35 years, 49 % ever injected drugs). Major implementation challenges included: slow and complex ethics and governance requirements in each jurisdiction, and challenging logistical arrangements and participant access constraints in the prisons. Major facilitators included use of point-of-care testing allowing immediate feedback of results, strong support from jurisdictional stakeholders in correction and public health sectors, flexibility in the timing and detailed planning for each site, and computer tablet-based data collection.

Conclusion: The high participation and informative findings indicated clear feasibility of this improved surveillance system. Strong stakeholder engagement and flexibility in logistics facilitated successful implementation of multi-jurisdictional prison-based surveillance.

Keywords: Blood borne viruses; Facilitators; Hepatitis C; People who inject drugs; Prison; Surveillance.